By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Pharmacyclics, Inc. 

995 East Arques Avenue

Sunnyvale  California  94086  U.S.A.
Phone: 408-774-0330 Fax: 408-774-0340


Company News
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA® (ibrutinib) Data To Be Presented Across Multiple Histologies, Including In Eight Oral Presentations, At 2014 American Society of Hematology Annual Meeting 11/6/2014 9:15:21 AM
Pharmacyclics, Inc. (PCYC), AstraZeneca PLC (AZN) Partnership Holds Tumor Promise: Citi 11/5/2014 5:31:02 PM
Pharmacyclics, Inc. (PCYC) Reports Third Quarter 2014 Financial Results And Provides Clinical Program Update 11/5/2014 7:47:12 AM
AstraZeneca PLC (AZN) And Pharmacyclics, Inc. (PCYC) Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers 11/5/2014 7:32:36 AM
AstraZeneca PLC (AZN) And Pharmacyclics, Inc. (PCYC) Enter Immuno-Oncology Clinical Trial Collaboration With IMBRUVICA® In Solid Tumors 11/4/2014 9:47:52 AM
AstraZeneca PLC (AZN) Strengthens Cancer Biz With Johnson & Johnson (JNJ), Pharmacyclics, Inc. (PCYC) Deals 11/4/2014 6:06:33 AM
Pharmacyclics, Inc. (PCYC) Announces Conference Call To Discuss Third Quarter Financial Results 10/29/2014 7:22:16 AM
Pharmacyclics, Inc. (PCYC) Files Supplemental New Drug Application For IMBRUVICA® For Waldenstrom's Macroglobulinemia 10/20/2014 8:29:51 AM
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA® (ibrutinib) Now Approved In Europe for Treatment Of Two Blood Cancers 10/17/2014 8:02:09 AM
Pharmacyclics, Inc. (PCYC) Enters Into Agreement With Roche (RHHBY) To Evaluate IMBRUVICA® And GAZYVA® In Lymphoma And Leukemia 10/16/2014 1:04:05 PM